The Evolving Role of Radioactive Iodine in Thyroid Cancer Diagnosis and Treatment

• Kulkarni, Kanchan ^[1] ; Avram, Anca M. Avram ^[1]
  1. [1] MD
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 54, Nº. 3, 2025, págs. 397-406
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Thyroid cancer is becoming more prevalent in the United States with rates having tripled over the last 40 y.1 Radioactive iodine (RAI) remains the mainstay of therapy for differentiated thyroid cancer (DTC) following surgery. Use of RAI has made remarkable strides, since its first use in 1942 by Saul Hertz for Graves’disease and its subsequent use in patients with cancer when RAI uptake was demonstrated in thyroid cancer metastases.2 The treatment landscape has evolved in many ways including risk adapted approach, careful selection of patients, dosimetry-guided approach for advanced metastatic disease, as well use of RAI use for radioiodine refractory thyroid cancer following sensitization. In this article, we summarize the changing role of radioiodine for diagnosis and treatment.